MaryAnn Zhang1, Yuqing Zhang2, Robert Terkeltaub3, Clara Chen2, Tuhina Neogi2. 1. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Boston University School of Medicine, Boston, Massachusetts. 3. VA San Diego Healthcare System, University of California San Diego, La Jolla, California.
Abstract
OBJECTIVE: To determine the relationship between omega-3 polyunsaturated fatty acid (n-3 PUFA) consumption (dietary or supplemental) and risk of gout flares. METHODS: We used data from the Boston University Online Gout Study, an internet-based case-crossover study conducted from February 2003 to January 2012. At the times of gout flares (hazard period) and during gout flare-free periods (control periods), participants completed questionnaires regarding exposures, including supplements and diet, during the preceding 48 hours. We examined the relationship of self-reported n-3 PUFA-rich supplements and fish intake with the risk of recurrent gout flares using conditional logistic regression, adjusting for total purine intake, diuretic use, and other urate-lowering or flare prophylactic medications (allopurinol, nonsteroidal antiinflammatory drugs, or colchicine). RESULTS: Of the 724 participants, 85% met the 1977 American College of Rheumatology preliminary criteria for the classification of the acute arthritis of primary gout. Twenty-two percent of the participants reported some form of n-3 PUFA consumption (supplements, 4.6%; dietary fatty fish, 19%) in the 48 hours preceding a gout flare or flare-free period. The adjusted odds ratios were 1.01 (95% confidence interval [95% CI] 0.63-1.60; P = 0.98) for all 3 supplements combined and 0.74 (95% CI 0.54-0.99; P = 0.04) for consumption of ≥2 n-3 PUFA-rich fish servings. CONCLUSION: Dietary n-3 PUFA-rich fish consumption, when adjusted for total purine intake, was associated with lower risk of recurrent gout flares, whereas n-3 PUFA supplementation alone, as taken in a self-directed manner, was not. Consumption of specific sources and adequate doses of n-3 PUFA for gout flare prevention warrants further study in an adequately powered clinical trial.
OBJECTIVE: To determine the relationship between omega-3 polyunsaturated fatty acid (n-3 PUFA) consumption (dietary or supplemental) and risk of gout flares. METHODS: We used data from the Boston University Online Gout Study, an internet-based case-crossover study conducted from February 2003 to January 2012. At the times of gout flares (hazard period) and during gout flare-free periods (control periods), participants completed questionnaires regarding exposures, including supplements and diet, during the preceding 48 hours. We examined the relationship of self-reported n-3 PUFA-rich supplements and fish intake with the risk of recurrent gout flares using conditional logistic regression, adjusting for total purine intake, diuretic use, and other urate-lowering or flare prophylactic medications (allopurinol, nonsteroidal antiinflammatory drugs, or colchicine). RESULTS: Of the 724 participants, 85% met the 1977 American College of Rheumatology preliminary criteria for the classification of the acute arthritis of primary gout. Twenty-two percent of the participants reported some form of n-3 PUFA consumption (supplements, 4.6%; dietary fatty fish, 19%) in the 48 hours preceding a gout flare or flare-free period. The adjusted odds ratios were 1.01 (95% confidence interval [95% CI] 0.63-1.60; P = 0.98) for all 3 supplements combined and 0.74 (95% CI 0.54-0.99; P = 0.04) for consumption of ≥2 n-3 PUFA-rich fish servings. CONCLUSION: Dietary n-3 PUFA-rich fish consumption, when adjusted for total purine intake, was associated with lower risk of recurrent gout flares, whereas n-3 PUFA supplementation alone, as taken in a self-directed manner, was not. Consumption of specific sources and adequate doses of n-3 PUFA for gout flare prevention warrants further study in an adequately powered clinical trial.
Authors: Catherine Hill; Tiffany K Gill; Sarah Appleton; Leslie G Cleland; Anne W Taylor; Robert J Adams Journal: Rheumatology (Oxford) Date: 2009-01-27 Impact factor: 7.580
Authors: Kimberly T Sibille; Christopher King; Timothy J Garrett; Toni L Glover; Hang Zhang; Huaihou Chen; Divya Reddy; Burel R Goodin; Adriana Sotolongo; Megan E Petrov; Yenisel Cruz-Almeida; Matthew Herbert; Emily J Bartley; Jeffrey C Edberg; Roland Staud; David T Redden; Laurence A Bradley; Roger B Fillingim Journal: Clin J Pain Date: 2018-02 Impact factor: 3.442
Authors: Regan L Bailey; Jaime J Gahche; Paige E Miller; Paul R Thomas; Johanna T Dwyer Journal: JAMA Intern Med Date: 2013-03-11 Impact factor: 21.873
Authors: Jennifer Liddle; Jane C Richardson; Samantha L Hider; Christian D Mallen; Lorraine Watson; Priyanka Chandratre; Edward Roddy Journal: Rheumatol Adv Pract Date: 2021-08-13